- Home
- CRGY vs BCYC Comparison
CRGY vs BCYC Comparison
Compare CRGY & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGY
- BCYC
- Stock Information
- Founded
- CRGY 1986
- BCYC 2009
- Country
- CRGY United States
- BCYC United Kingdom
- Employees
- CRGY N/A
- BCYC N/A
- Industry
- CRGY Oil & Gas Production
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- CRGY Energy
- BCYC Health Care
- Exchange
- CRGY Nasdaq
- BCYC Nasdaq
- Market Cap
- CRGY 2.0B
- BCYC 1.7B
- IPO Year
- CRGY N/A
- BCYC 2019
- Fundamental
- Price
- CRGY $16.63
- BCYC $13.34
- Analyst Decision
- CRGY Buy
- BCYC Buy
- Analyst Count
- CRGY 11
- BCYC 9
- Target Price
- CRGY $17.56
- BCYC $34.50
- AVG Volume (30 Days)
- CRGY 3.5M
- BCYC 417.9K
- Earning Date
- CRGY 03-03-2025
- BCYC 02-18-2025
- Dividend Yield
- CRGY 2.89%
- BCYC N/A
- EPS Growth
- CRGY 42.32
- BCYC N/A
- EPS
- CRGY 0.53
- BCYC N/A
- Revenue
- CRGY $2,713,358,000.00
- BCYC $36,898,000.00
- Revenue This Year
- CRGY $25.83
- BCYC $40.69
- Revenue Next Year
- CRGY $27.52
- BCYC N/A
- P/E Ratio
- CRGY $31.39
- BCYC N/A
- Revenue Growth
- CRGY 12.60
- BCYC 48.60
- 52 Week Low
- CRGY $9.88
- BCYC $12.17
- 52 Week High
- CRGY $16.94
- BCYC $28.67
- Technical
- Relative Strength Index (RSI)
- CRGY 74.43
- BCYC 34.88
- Support Level
- CRGY $12.90
- BCYC $13.20
- Resistance Level
- CRGY $16.94
- BCYC $15.43
- Average True Range (ATR)
- CRGY 0.41
- BCYC 0.89
- MACD
- CRGY 0.19
- BCYC 0.16
- Stochastic Oscillator
- CRGY 90.36
- BCYC 6.17
About CRGY Crescent Energy Company
Crescent Energy Co is an independent energy company with a portfolio of assets in key basins across the lower 48 states. The company maintains a diverse portfolio of assets in key basins across the United States, including the Eagle Ford, Rockies, Barnett, Permian, and Mid-Con. It seeks to deliver attractive risk-adjusted investment returns and predictable cash flows across cycles with a focus on operated oil and gas assets complemented by non-operated assets, mineral and royalty interests, and midstream infrastructure.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.